The results of retatrutide's Phase 3 trials are so dramatic—weight losses of 28% of body weight, surpassing bariatric surgery in some cases—that they have generated something clinical researchers never want to see: lawsuit before approval. As the data has been disseminated in scientific, informative and social media, thousands of people with severe obesity who have been looking for a solution for years have begun to search the Internet for how to access the molecule. And they have found it.
Chemical synthesis laboratories in China, operating on the margins of international drug regulation, have begun producing retatrutide as an "investigational peptide"—a category that in many countries is not subject to the same controls as prescription drugs—and selling it through e-commerce platforms and specialized websites. The price varies, but is significantly lower than what the drug would have once approved and marketed by Eli Lilly.
Why it is dangerous
There are several reasons why self-medication with unregulated retatrutide is a serious medical problem, beyond the generic argument that "buying drugs without a prescription is bad." The first is the purity of the compound. Retatrutide is a complex peptide molecule that requires precise synthesis processes. A defective synthesis or impurity of the compound can produce anything from an inactive molecule to degradation products with unpredictable effects. Without regulatory control, there is no way to know exactly what is in what arrives in the mail.
The second reason is monitoring. In Eli Lilly's clinical trials, all participants are regularly monitored: blood tests, assessment of side effects, supervised dose adjustment. Known adverse effects of retatrutide include nausea, vomiting, diarrhea, and other gastrointestinal symptoms that are managed with progressive dose adjustments in clinical trials. Someone who self-medicates without medical supervision does not have that support.
What science still doesn't know about retatrutide (May 2026)
- Long-term cardiovascular safety: TRIUMPH-CVOT trial does not end until 2028
- Long-term effects on muscle mass: under evaluation (as with all GLP-1)
- Safety during pregnancy: no data — contraindicated in pregnant women
- Effects of abrupt interruption: risk of rebound effect, profile not completely defined
- Interactions with other drugs: limited database outside trials
- Efficacy and safety in adolescents: no studies
The third reason, and perhaps the most important, is what is not yet known. Phase 3 trials of retatrutide are ongoing precisely because regulatory approval requires safety and efficacy data in thousands of patients over long periods. The data available today is promising but incomplete. The Cardiovascular Outcomes Trial (TRIUMPH-CVOT), which will evaluate whether retatrutide increases or reduces the risk of heart attack, stroke and cardiovascular death, will not have results until 2028. That is critical information for anyone with cardiovascular risk factors.
The worrying precedent
This is not the first time this has happened in the era of GLP-1 drugs. When Ozempic became a media phenomenon for its effectiveness in losing weight, unregulated versions of semaglutide appeared on the market. The FDA issued warnings, seized shipments and prosecuted compounding pharmacy companies that produced unapproved versions. With retatrutide, the phenomenon arrives before approval, with even more spectacular preliminary data, and in a context of social networks where the testimonies of people who "are already trying it" go viral and create additional demand.
Medical Warning: Retatrutide is not approved by the FDA, EMA, or AEMPS as of May 2026. Any product marketed as "retatrutide" outside of an authorized clinical trial has not been evaluated by any regulatory agency. Doctors recommend not using these products without clinical supervision.
What can be done now
For people with severe obesity seeking therapeutic options while awaiting approval of retatrutide, there are approved and proven alternatives. Tirzepatide (Mounjaro), approved for both type 2 diabetes and obesity, produces weight losses of between 15% and 22.5% in clinical trials, and is available in many countries by prescription. Semaglutide (Wegovy for obesity, Ozempic for diabetes) is also approved. These drugs, taken under medical supervision with regular monitoring, have well-documented safety profiles. Retatrutide, when approved, will represent an additional step in effectiveness. But that step is not yet safely available.
Share this article
